You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 155 No. 21, 27 NOVEMBER 1995 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Review Articles
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (42)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

A New Typhoid Vaccine Composed of the Vi Capsular Polysaccharide

Stanley A. Plotkin, MD; Nancy Bouveret-Le Cam, MD

Arch Intern Med. 1995;155(21):2293-2299.


Abstract



Typhoid is still prevalent in many parts of the world. We reviewed all published and unpublished studies of a newly licensed vaccine composed of the Vi capsular polysaccharide of Salmonella typhi, the causative agent of the disease, which had been licensed previously outside the United States. These included observational studies and double-blind randomized studies done in the United States, Europe, and the developing world in which children and adults unexposed to typhoid or those living in endemic areas were enrolled. A single dose of 25 µg of the purified polysaccharide was given by intramuscular injection. The vaccine was well tolerated, inducing only minor reactions in fewer than 10% of subjects. An antibody response occurred in about 90% of subjects and lasted about 3 years. Seroconversion was shown in children as young as 2 years. Protective efficacy was evaluated in two studies conducted in areas in which typhoid is endemic; the efficacy was 55% and 75%, respectively, in adults and in children older than 5 years. The Vi vaccine compares favorably with other typhoid vaccines in regard to safety, patient compliance, immunogenicity, and efficacy. Vi polysaccharide is a well-standardized antigen that is effective in a single parenteral dose, is safer than whole-cell vaccine, and may be used in children 2 years of age or older.

(Arch Intern Med. 1995;155:2293-2299)



Author Affiliations



From the Pasteur Mérieux Connaught, Marnes-la-Coquette, France.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Vaccinations for the Pediatric Traveler
Mackell
Clinical Infectious Diseases 2003;37:1508-1516.
ABSTRACT | FULL TEXT  

Travel Vaccines and Elderly Persons: Review of Vaccines Available in the United States
Ericsson et al.
Clinical Infectious Diseases 2001;33:1553-1556.
ABSTRACT | FULL TEXT  

Acute Systemic Inflammation Impairs Endothelium-Dependent Dilatation in Humans
Hingorani et al.
Circulation 2000;102:994-999.
ABSTRACT | FULL TEXT  

Typhoid Fever
Zenilman
JAMA 1997;278:847-850.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1995 American Medical Association. All Rights Reserved.